The Burrill Report
The Burrill Report (April 2, 2012): Understanding the Shifting Patent Landscape (.MP3,11.84 Mb)
The intellectual property landscape for life sciences companies is in flux. A recent U.S. Supreme Court ruling that invalidated a Prometheus Laboratories patent has diagnostic makers struggling to understand its ramifications. The Indian government’s compulsory license for Bayer’s patented cancer drug Nexavar has drugmakers thinking about how to protect their intellectual property in emerging markets. And patent reform, passed six months ago, still brings uncertainty and change to the industry. We spoke to Courtenay Brinckerhoff, partner with Foley & Lardner, about these developments, how significant these changes are, and whether life sciences companies need to rethink their IP strategies.
March 30, 2012